PhaSER Biomedical and the Sanders TDI partner for clinical drug discovery research
PhaSER will provide 8HUM mouse models for the TDI to accelerate a pipeline of novel therapeutic targets
Read More
Tag: Sanders Tri-Institutional Therapeutic Discovery Institute
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
